BioLight subsidiary files IND for study of glaucoma treatment

ViSci, a wholly owned subsidiary of BioLight, has filed an investigational new drug application with the U.S. Food and Drug Administration regarding a potential study of a glaucoma treatment, according to a press release. The company is applying to conduct a phase 1/2a clinical study of a proprietary subconjunctival latanoprost controlled-release insert for the treatment of glaucoma.

Full Story →